Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases

Livio Pagano, Marie von Lilienfeld-Toal, Jörg Janne Vehreschild, Oliver Cornely, Francesca Compagno, Hans H Hirsch

Risultato della ricerca: Contributo in rivistaArticolo in rivista

25 Citazioni (Scopus)

Abstract

Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely as possible, since the most important protection for patients with malignant disease is the best-possible control of the underlying disease.
Lingua originaleEnglish
pagine (da-a)1-7
Numero di pagine7
RivistaLeukemia
Volume2020
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • covid, hematological malignancies

Fingerprint Entra nei temi di ricerca di 'Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases'. Insieme formano una fingerprint unica.

Cita questo